Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.26) by 30.77 percent. The company reported quarterly sales of $344.000 thousand which missed the analyst consensus estimate of $1.041 million by 66.97 percent. This is a 82.70 percent decrease over sales of $1.988 million the same period last year.